PEG-G-CSF

ApprovedSmall molecule

Sanofi

PEG-G-CSF is one of 61 small molecule programs targeting Neutropenia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

Prostate CancerActive, not recruiting

NeutropeniaPhase 2

Active, not recruiting

Prostate CancerApproved

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

PEG-G-CSF

Sanofi

Approved

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neutropenia3 trials

Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

Completed·DDong-A ST Co., Ltd.·Phase 2·NCT01923545·61 enrolled

Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

Completed·DDong-A ST Co., Ltd.·Phase 3·NCT01674855·74 enrolled

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

Active, not recruiting·KKexing Biopharm Co., Ltd.·Phase 3·NCT06711523·250 enrolled

Prostate Cancer1 trial

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

Completed· Sanofi logo

Sanofi·Phase 4·NCT02441894·21 enrolled

Clinical Trial1 trial

Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients

Unknown status·SShandong University·Phase 2·NCT03045627·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PEG-G-CSF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG-G-CSF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG-G-CSF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

PEG-G-CSF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neutropenia3 trials

Prostate Cancer1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News